GlobeNewswire by notified

Ascom launches Activity Monitoring, an innovative software solution for long-term care homes

Share

Ascom Activity Monitoring is an end-to-end solution for long-term care that monitor and predict a deterioration in the health of residents. Built on top of Ascom SmartSense, this state-of-the-art and fully interoperable software allows the integration of external sensors and monitors movements and wander behavior, detects potential falls, and monitors typical sleep patterns, etc. of long-term care home residents. Active Monitoring also optimizes workflow efficiency for the caregivers while preserving residents' lifestyle, privacy and safety.

The Ascom Activity Monitoring solution is part of the company's strategy to address the growing market for smart solutions in the long-term care industry. According to studies by the United Nations, the number of people worldwide aged 65 and older is expected to rise to 1.5 billion by 2050, compared to 702 million in 20191. The number of people aged 80 years or older is expected to grow even faster.

What is the Ascom Activity Monitoring solution?
With the Activity Monitoring solution, Ascom provides an end-to-end solution for long-term care. The Ascom SmartSense algorithm converts incoming sensor data into statuses and warnings as needed and enables caregivers to have a better and continuous health update of the resident, predict a health deterioration, and rapidly modify the care provided to prevent possible consequences. When paired with Ofélia or Unite, alarms can be customized to each resident’s needs and sent to the right person, to the right device, and at the right time. Since the Ascom Activity Monitoring system is based on open integration infrastructure, third-party sensors, smart cameras, or other smart sensors can be easy integrated. 
Ascom SmartSense meets regional and national regulatory criteria. 

How does it work?
A variety of sensors are positioned thoughtfully across the residents' rooms. An infrared ceiling detector can track movement, a door detector senses wandering, and a mattress detector looks for potential falls. Caregivers may easily integrate the sensors that are most appropriate for a resident's needs and confirm the resident's condition by consolidating data from multiple sources and presenting an overview of the resident on a single dashboard. Dashboards are available to caregivers on a variety of devices, such as professional smartphones like Myco 4 and ward computers.

Providing added value to residents and caregivers
By observing residents' overall lifestyle patterns, caregivers can enhance the patient’s experience in terms of comfort, dignity preservation, and maintaining the resident's autonomy and privacy. Caregivers can also predict how much staff and equipment will be needed, which improves timeliness and reduces costs. It is also possible to detect a deterioration in a resident's health at an early stage if their lifestyle deviates from the norm. Caregivers are also able to limit the number of rounds (particularly when patients are resting and do not want to be disturbed) and concentrate on the residents who need it the most at any given time, all thanks to the global view of the various statuses of residents on the ward in real-time (virtual round). 

The introduction of the Ascom Activity Monitoring solution addresses the growing market demand for smart solutions in the long-term care and home care industry in view of the increasing number of residents that are becoming more and more dependent, the shortage of staff, and cost-efficient budgets. The Ascom Activity Monitoring solution enhances outcomes through the digitization of care. 

1 https://www.un.org/en/development/desa/population/publications/pdf/ageing/WorldPopulationAgeing2019-Highlights.pdf, Page 5, Table 1

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.21.5.2024 02:25:00 CEST | Press release

SIMLANDI is the first interchangeable high-concentration, citrate-free biosimilar to Humira® REYKJAVIK, ICELAND & PARSIPPANY, NJ— Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Alvotech (NASDAQ: ALVO), today announced the availability of SIMLANDI (adalimumab-ryvk) injection in the U.S., as an interchangeable biosimilar to Humira for the treatment of adult rheumatoid arthritis, juvenile idiopathic arthritis, adult psoriatic arthritis, adult ankylosing spondylitis, Crohn’s disease, adult ulcerative colitis, adult plaque psoriasis, adult hidradenitis suppurativa and adult uveitis. “We are proud to make SIMLANDI available in the U.S. to patients and providers,” said Thomas Rainey, Senior Vice President, U.S. Market Access at Teva. “Biosimilars create opportunities for cost savings across the healthcare system, and SIMLANDI’s launch now offers the first citrate-free, high-concentration biosimilar to be designated interchangeable to Hu

IDEX Biometrics – Number of shares in Tranche 1 vs Tranche 2 in the private placement on 15 May 202420.5.2024 23:52:54 CEST | Press release

Reference is made to the stock exchange announcement by IDEX Biometrics ASA (the “Company”) on 15 May 2024 regarding a successful private placement of shares. By inadvertence, the announcement contained a slight error in the allocation of private placement shares between Tranche 1, as issued by the Board pursuant to an authorization to issue shares granted by the extraordinary general meeting dated 21 December 2023, and Tranche 2, to be issued subject to approval by an extraordinary general meeting to be called and scheduled for on or about 12 June 2024. The correct number of Tranche 1 shares is 27,940,213, and the correct number of Tranche 2 shares is 5,393,120, each having a par value of NOK 0.15, with a subscription price of NOK 1.65 per share in the private placement. Consequently, following the issuance of Tranche 1 shares, the Company's share capital is increased with NOK 4,191,031.95 from NOK 42,018,983.25 to NOK 46,210,015.20, and the Company will have 308,066,768 shares issued

INVNT™ ANNOUNCED AS SPONSOR AND CO-PRODUCER OF DISCOVERY STAGE AT SXSW SYDNEY® 202420.5.2024 23:00:00 CEST | Press release

Also named as an endorsed Creative Experiential Partner for the 2024 event Sydney, May 20, 2024 (GLOBE NEWSWIRE) -- INVNT™, the Experiential Disrupter Agency, has today been announced as the sponsor and co-producer of the SXSW Sydney 2024 Discovery Stage after a successful collaboration at last year’s inaugural event. For the second consecutive year, INVNT will bring its world-class expertise in production and innovative brand storytelling and “Challenge Everything” ethos to SXSW Sydney, where it will continue its legacy of hosting, curating and presenting the Discovery Stage and activating across the event’s key pillars of Tech & Innovation, Music, Games and Screen. Featured within the SXSW Sydney Tech & Innovation Expo, the 2024 Discovery Stage will play host to inspiring innovation leaders who are redefining industry norms and will be a place to explore the latest developments in technology and meet startup founders who are poised to disrupt the status quo. As last year’s Discovery

Nokia Corporation: Repurchase of own shares on 20.05.202420.5.2024 21:30:00 CEST | Press release

Nokia Corporation Stock Exchange Release 20 May 2024 at 22:30 EEST Nokia Corporation: Repurchase of own shares on 20.05.2024 Espoo, Finland – On 20 May 2024 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL370,3933.56CEUX--BATE--AQEU--TQEX--Total370,3933.56 * Rounded to two decimals On 25 January 2024, Nokia announced that its Board of Directors is initiating a share buyback program to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The first phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 4 April 2023 started on 20 March 2024 and ends by 18 December 2024 with a maximum aggregate purchase price of EUR 300 million. Total cost of tra

Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM20.5.2024 20:15:00 CEST | Press release

Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM NOTUS results confirm landmark data from the phase 3 BOREAS study and show Dupixent significantly reduced exacerbations by 34% and improved lung function, compared to placebo, in uncontrolled chronic obstructive pulmonary disease (COPD) with evidence of type 2 inflammationData support the potential of Dupixent as the first new treatment approach in more than a decadeand first-ever targeted therapy for COPD Paris and Tarrytown, N.Y. May 20, 2024. Late-breaking data were presented from the NOTUS phase 3 study evaluating the investigational use of Dupixent® (dupilumab) as an add-on maintenance treatment in adults with uncontrolled COPD on maximal standard-of-care inhaled therapy (nearly all on triple therapy) and evidence of type 2 inflammation (i.e., blood eosinophils ≥300 cells per μL). The NOTUS study confirmed the positive results demonstrated in the landmark phase 3 BOREAS s

HiddenA line styled icon from Orion Icon Library.Eye